Tag Archives: pfe

Pfizer Breast-Cancer Drug Scores, But Street Cautious

Big pharma Pfizer (PFE) was down 2.5% in morning trading on the stock market today after its breast-cancer drug palbociclib did well in trials but fell a bit short of sky-high expectations. At the American Association for Cancer Research meeting on Sunday, Pfizer presented final results from its phase-two trial of palbo in patients with metastatic breast cancer. As IBD reported last month, investors were greatly interested in the presentation

Amgen Stock Gets Bump Up On Cholesterol Drug Data

Amgen (AMGN) stock was up 2.5% in afternoon trading on the stock market today after the company presented five studies on its new cholesterol drug over the weekend. Results eased safety concerns raised earlier in the month. Competitors Regeneron (REGN), Sanofi (SNY), Pfizer (PFE) and Bristol-Myers Squibb (BMY) also presented data, but their shares were up a fraction or flat Monday afternoon. At the American College of Cardiology meeting, Amgen

New Cholesterol Fighters To Take Center Stage At ACC

In recent decades, high cholesterol has been Big Pharma’s gravy train. The statins, oral drugs that lower “bad” cholesterol, turned into the best-selling drugs in history, with Pfizer’s Lipitor peaking at nearly $14 billion in 2006 sales. Now, however, all the statins have gone off-patent or are about to. So Pfizer (PFE) and a passel of other companies — led by Amgen (AMGN), Regeneron (REGN) and Regeneron’s partner Sanofi (SNY) — are turning to a